<SUBMISSION>
<ACCESSION-NUMBER>0001193125-09-175165
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090814
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20090814
<DATE-OF-FILING-DATE-CHANGE>20090814
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>PRO PHARMACEUTICALS INC
<CIK>0001133416
<ASSIGNED-SIC>2834
<IRS-NUMBER>043562325
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31791
<FILM-NUMBER>091012274
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
<PHONE>6175590033
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>189 WELLS ST
<STREET2>STE 200
<CITY>NEWTON
<STATE>MA
<ZIP>02459
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>Form 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Current Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities
Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>August 14, 2009 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Date of Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Date of earliest event reported) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>PRO-PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of Registrant as specified in its
charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-32877</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>7 Wells Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Newton, Massachusetts 02459 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(617) 559-0033 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(Registrant&#146;s
telephone number, including area code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On
August&nbsp;14, 2009, Pro-Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a news release announcing its financial results for the three and sis months ended June&nbsp;30, 2009. A copy of the news release is attached as Exhibit 99.1 to this
Current Report on Form 8-K. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information in this Current Report (including the exhibit) is furnished pursuant to Item&nbsp;2.02 and
shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(a) Financial
Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not applicable. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(c) Shell Company Transactions </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT FACE="Times New Roman" SIZE="2">Not
applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">News release of Pro-Pharmaceuticals, Inc., dated August 14, 2009, entitled &#147;Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results&#148;.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">PRO-PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Anthony D. Squeglia</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Anthony D. Squeglia</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Date: August&nbsp;14, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">News release dated August 14, 2009 entitled &#147;Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results&#148;.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>News release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g42314g27u37.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>Pro-Pharmaceuticals Reports Second Quarter </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B><I>and First Six Months 2009 Financial Results </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Newton, MA &#150; August&nbsp;14, 2009
&#150; Pro-Pharmaceuticals, Inc. (OTCBB: PRWP)</B>, a developer of carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the second quarter and first six months of fiscal 2009. These
results are included in the Company&#146;s Quarterly Report on Form 10-Q for the three- and six-month period ended June&nbsp;30, 2009, which has been filed with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">For the three months ended June&nbsp;30, 2009, the Company reported a net loss applicable to common stock of $3,337,000, or ($0.07) per share, basic and fully diluted, compared with a net loss of $615,000, or ($0.01)
per share for the same period in 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For the six months ended June&nbsp;30, 2009, the Company reported a net loss applicable to common stock of
$6,196,000 or ($0.13) per share, basic and fully diluted, compared with a net loss of $2,684,000, or $(0.06) per share for the same period in 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During
the three months ended June&nbsp;30, 2009, the Company closed two tranches of Series B-2 Redeemable Convertible Preferred Stock financings resulting in net proceeds of approximately $1,274,000. These transactions bring the total raised to $3.2
million of the $6 million commitment from the 10X Fund. At June&nbsp;30, 2009, the Company had approximately $982,000 of unrestricted cash and cash equivalents to fund future operations. On August&nbsp;11, 2009, the Company amended its Series B-1
agreement with the 10X Fund to extend the redemption date of the Series B-1 Preferred Stock from thirteen months to nineteen months. Also, the final purchase date for the sale of Series B-2 Preferred Stock to the 10X Fund, under the 10X Agreement,
was extended from August&nbsp;11, 2009 to February&nbsp;11, 2010. On August&nbsp;12, 2009, the Company completed a closing for gross proceeds of $300,000, net cash proceeds of $287,000, on its offering of Series B-2 Preferred Stock for a total of
150,000 shares of Series B-2 and warrants to purchase shares of common stock. The Company believes that with the funds from the August&nbsp;12, 2009 closing of the Series B-2 and cash on hand at June&nbsp;30, 2009, there is sufficient cash to fund
operations into October 2009. The Company is actively pursuing efforts to raise additional capital but there can be no assurance that such efforts will be successful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT
FACE="Times New Roman" SIZE="2">Research and development expense for the second quarter of 2009 was $423,000, compared with $744,000 for the same period in 2008. The decrease was due primarily to overall lower activity in clinical and pre-clinical
programs as a result of cost containment measures. Research and development expense for the six-month period ended June&nbsp;30, 2009, decreased compared to the same period in 2008, due primarily to overall lower activity as a result of cost
containment measures, and decreased salaries and stock-based compensation. Also, during the three and six-months ended June&nbsp;30, 2008, the Company incurred costs related to the filing of the DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Drug Master File with the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">General and Administrative expense for
the second quarter of 2009 was $1,569,000, compared with $1,130,000 for the same period in 2008. The increase was due primarily to increased stock-based compensation charges. The increase in general and administrative expense for </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">the three and six- months ended June&nbsp;30, 2009 as compared to the same periods in 2008, is due to increased stock-based compensation and business
development expenses, offset by decreased payroll. The primary reason for the increase for the six-months ended June&nbsp;30, 2009, as compared to the same period in 2008, is due to increased stock-based compensation and increased payroll due to the
recognition of severance obligations related to the departure of our former chief executive officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">&#147;We are laying the
groundwork for a Phase lll trial to submit a new drug application (NDA) to the Food and Drug Administration (FDA) to commercialize DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>,&#148; said Theodore Zucconi, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals. &#147;Our plan is to initiate a Phase lll trial for DAVANAT<FONT
FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> to treat late-stage colorectal cancer patients after we raise additional funds. We also are actively engaged in discussions with
a potential partner to distribute DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> internationally, in countries with their own approval process.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2"><B>About DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;"><FONT FACE="Times New Roman" SIZE="2">DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>,
the Company&#146;s lead product candidate, is a carbohydrate polymer composed of mannose and galactose.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&#146;s
mechanism of action is based on interacting with lectins on the cell surface.&nbsp;DAVANAT<FONT FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> targets specific lectin receptors
(galectins) that are over-expressed on cancer cells. Current research indicates that galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis and tumor metastasis.&nbsp;DAVANAT<FONT
FACE="Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> is a drug that is not yet approved for commercial use by the FDA. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Pro-Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Pro-Pharmaceuticals, OTCBB: PRWP, is engaged in the discovery, development and
commercialization of carbohydrate therapeutics for advanced treatment of cancer and fibrosis.&nbsp;Initially, the product pipeline is focused on increasing the efficacy and decreasing the toxicity of chemotherapy drugs.&nbsp;The Company is
headquartered in Newton, Mass.&nbsp;Additional information is available at www.pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">FORWARD LOOKING STATEMENTS: Any statements in this
news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words &#147;believes,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;expects,&#148; and similar expressions,
constitute forward-looking statements as defined in the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management&#146;s current expectations and are subject
to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or
suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical
trials of our product candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible
development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of government regulation of our activities, facilities and
personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses and accumulated deficit; and economic conditions
related to the biotechnology and biopharmaceutical industry. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on forward-looking statements. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">More information about those risks and uncertainties is contained and discussed in the &#147;Management Discussion and
Analysis of Financial Condition and Results of Operations&#148; and &#147;Risk Factors&#148; sections of the Company&#146;s most recent quarterly or annual report and in the Company&#146;s other reports filed with the Securities and Exchange
Commission. The forward-looking statements represent the Company&#146;s views as of the date of this news release and should not be relied upon to represent the Company&#146;s views as of a subsequent date. While the Company anticipates that
subsequent events may cause the Company&#146;s views to change, the Company disclaims any obligation to update such forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contact:
Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; squeglia@pro-pharmaceuticals.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">DAVANAT is a registered trademark of Pro-Pharmaceuticals.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Condensed Consolidated Statements of Operations </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Three Months</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Six Months</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(in thousands except per share data)<BR>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">744</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">576</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Other income and (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Change in fair value of warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(1,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(5,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Preferred stock dividends and accretion costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Net loss applicable to common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(615</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(6,196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(2,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Shares used in computing basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">50,357</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">47,929</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">48,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">45,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Condensed Consolidated Balance Sheet Data </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>At</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;June&nbsp;30,&nbsp;&nbsp;</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>At</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>in&nbsp;thousands&nbsp;(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(3,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">(469</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g42314g27u37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g42314g27u37.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.0&0`P$1``(1`0,1`?_$`,\``0`#`0`#`0$!`0``
M```````("0H'!`4&`0L"`P$!``$%`0$!``````````````8#!`4'"`(!"1``
M``8"`@`#`@D)!04)`````@,$!08'`0@`"1$2$Q0*(2(5%G:V=[<X,4$C%S=X
MN#DZ,C2T=7E1<K*SM6&!L3-S)'0V&!$``@$#`@0"!@(,"0H%!0```0(#``0%
M$08A,1('01-187$B%`B!,I&QP;(C,W.S=+0U-J%"<L(T%74W./#1X5)B@D,D
MQ';2P[46%U-C1"9&_]H`#`,!``(1`Q$`/P#?QQ2G%*<4IQ2G%*<4KQEJU&VH
MU;BXJTR!O0)CUJY<M/*2HT2-*4,]2K5J3QEDITR<DL0S#!BP$`<9SG.,8YZ5
M6=@B`ER=`!Q))Y`#Q)I6.KML]XHPG%)-<NO"2EFJ0>ULD]VG0A+/2I!_'3+V
M:BPG`,)7*R_A`.4&!RG*%XY;0&B]-:#IOMOV2ZNC.;VCT7@T=H>9\0UQZ!_]
MH<3_`,0CBAI,_@M14ZN][[CU*@M?/32O53B"RM#EVL6OY`Y'FD29:L<UPG"2
M-[LH]I4M$U,QG(LKOT@%0L8"J`:'RY!MK?/;W";UL_)N%$&2B7IAF11J@')&
M4:!HO]G@5YH0===1W.X;S![FNVB]^U:;WXR>!]T<0?XK>OD>1!K:;KILK4VT
M<`2V#5$@`YH\9*3/S$LP6EDT0=QE>H-EDS3@TPQ`L#C&<ECQD:=2#'J$&&%_
M&YQ7N?:N9VCDCC<S%T/S1QQCD7_6C;Q'I'!E/!@#PK9^+RMEE[87-DVJ^(/!
ME/H8>!_@/,$BN^<CE9*G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2L5/O/VY>PD9MR"Z91*;JHA1$LI=CLJ?,<<]9L=K$=
MW:93%B"QRY\)/]J70QN31<DT+45Z292H,$-5@_`"0E=4]@=KX6?&3;IN8A+F
M([IHHV;B(U"(W4B\@Y+D=9U('!=..M*0GEX5D*QC&,8QC&,8QCPQC'P8QC'Y
M,8Q^;&.=*52JZ?7?]AU8_1D'^/7<MG^N:T5N;]OW7Y7[@J9%%WU:6N-@-UD5
M+)E,>?DN2T[@ESYE#%)FCU@F'L,G:,C`G=VI1G'C@(O*:0/P,)&6;C`\8+<&
MW,1NC&MB\S$);9N*GD\;:<'C;FK#[!'!@1PJPQV1O,7<BZLG*R#GZ&'H8>(^
MUS&AK>8TJS%[4V+C0@`:M;T:LP!?CZ8#%*8LX80>;(A>0(A^&/'.<^'/SMF0
M1S/&O)6(^P=*Z,1NI`QYD`U[#E*O5.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI7\XS7B7;56-UI[1[]/G:EMQ7%R:T6J@B];P1ZON0+X=8Y8V*#N
MYC`%H>7A0\N$L>LR=26E"7[0BSA*'!Z8163S"_U;W38[,Q7=O#=L[?9F#N\#
ME[(R3S)9H)8/?F7KZD0(L:>6I;7I?WO=<-T@S^X2VCR$=BMM$T4J:DA1JO$\
M>6F@TK:OIWL!9^P_5Q4>Q-D%',5K6!JPIF4A7-Y(V8Q1(RXBZ@*E[601Z>6P
MN2"1%NR4)7@$H"H'IY\N`YY^?6_-L8?:W>.^VKB2),+:YD1(&/7HGFK^"8GZ
MWEZF)M>94Z\=:B%W!'!DF@CXQ++H/9KR^CE6).M[HO`KJRD6^#SW`;2PK;"(
M7,=$ZVUY?-B%D@16:V,;W!TA@T,">'=7*W%6%ODJE<>H/`L:,DHLE')\A-\W
M/T,R^W]NGO+%VVM]BX:XV5/CQ)/?)8A#;LZ3'C,JB)1U1JB@%9=7U5M5TJ82
M0P?UD+(6L1M2FI<)H5)!\>7A[>-;P*;ON9,F@]>[-;-LY\>G#%JTR75=[,D;
M2VM8A>F:LRIG-R$[*(T)3:N--2GY"CR(."#1^E\7R^&/S:S^VK"X[EW6T-H2
M"7'29E[2T<MU`H]QY4)+Z>\!J-7\0.KQJ%30(U\UM;'5#+TK]G05FKU*U-VQ
M[VHU/]\]DMU-@];JKF,XF$;U?HG7Z6+8^QPN,Q5P-9!.[N1E22U.`4[BDRB.
M,"3AR=E:10I-5$%B3D`ZUWOO;9/RWW=KVUVGM_%Y;-6]O%)D+R]C#O+)(H?I
M4Z%EU4]8&OEQJR(J,0S&0W5U:X5ELK>&.24*"[,-22>.GW?0.%3$Z4-I=KHS
MM1N3U9;G6/([JL+5D!$IJRVI,6:8]/\`6B5V:&,T+DZKTXI`]HWM!+6)Y:U#
MFJ6+"R5QZ<1YH""\X@GS![-V5>;,P'>78%I%C\7F28[BVC^HEP59_=53T(4,
M4T4@C5$)17"@L:M<Q;6K6T.3LU"1R\&4>!Y^SP(.FG*J>/>IDWI;VT8H\^!>
MUZJLO@#PSC)?L]K68#X<^/@+S^?_`+O#EY\O+:[1NU]&1;\S%47DYU2CJ!HG
MLYO?)9K$-88.U3I_KQB:9)+$3I-(K"PM[.^."MK;51*F5.;6G7"/6H309`2(
M8P8#XBQC&<<V?NC>VW-FK`VX)GB%P6"=*-(3T=/5J%!T`ZAQ/IKP%+<JOO8^
MK7=[7C71%(K9JAI8&>KH4J<YJK16-`'[Y,0MQZM4L/((9Y`J4./HD&X%Y2`C
M%G\V,YY%K#N[L7+9&+'6-S,UW<2JB`P2*"S$!021H-2>9K4^Y-M9=[^ZRBHO
MP6I?7K77I"C4Z:Z^'*HO_GQ_O!_XL<V5XU!*V\[CR!^B>@NSLIBSTZQN31S4
MVW7R/2%B7J6MZ8WIJJ9^7-;NT.:,PE6WN3<M(`<0>4,)A1H,"#G&<8SS@?85
MK;7O<O#V=Y&DMI+F[9'1P&1T:Y0,K*=0RL"001H0=#746-57N(%8`J60$'D>
M(K&!)IQM1JSUCZ?]H,+[2-HI+L%8LJC0EFLML6V.P8#/T9TND#2[,C-"758>
M\.;>B0Q\D]P"K`N\4YX\`,3G"(%SOZSQVS-Y]WL[V>R&S</#MBU@DTR%M;>1
M-"1$C*[2J`BL2Y"=)3W@-0RAA4Q1;:ZOY<>]M&(`OUU70C@#Q/T^JM7O9K:=
MC,74MLS<$<<9-4MHE:R8F:1;&'ATCTJ@<I<&QE7JTS6](34;NV.+,K5&$>J`
M99H<AS^3/CSBGM#AL5<][<1@KI(;[#G,>41(JO'-&K.H+(0596`!T((J-8Z*
M-LI'"VC1>9IQX@C[55W:'=NNHK-U?U!&[YWM@1>T2:@Y2BEX;"LY8NM8N?&X
ME/R6%[<G(U2]FR(/J)?2&,T1V/T?ES_9YM3N3V-WS<=XKZ[VUMNY.S3DXS%Y
M%N!;>2/+ZNA5`0)];4``<]?&K^]Q5T<BS0P-\-UC31?=TX:\N&E=F]VWMRV;
MKZU6N;7394]M:;YO&VF<Z5V1*WN927+<V*&,"%M,>I`M7N`D:'U1X**R9Y"_
M-GRXQX\C_P`V.#PFWN[3X_;]I;66._JZV81P1I%'U,'U;H0*NIX:G34^-4=P
M0Q09#HA553H4Z``#Q]%1S[_=B-EY+:6K'7SI19<WKN]+'8K:V*FKG7$MD$-D
MQL%JNOIDXQN*Y?8J>2[DIY>HC[X,"?(@DGK6U)@S.`YP+$L^63:VT;3#9GNA
MW"L[>ZVY:26UC$L\:2Q^=<SQ+))T2`J3$'A!;F$D?3CPJYP=O;+%+?7BAH%*
MJ-0"-21J=#Z-1]DU9MTS;>J]V.NS7ZW)$\GOECL;";55MKEIQA[FIL:M1@C[
MH[.YQPA'&.<K:2T+T:(?QA9<L9S^7FH._FQ4[>]U,I@[6,1XF27XFV`&BB"?
MWU50.'3&W7$-/_IUC<O:"SOY(E&D9/4OL/'^#B/HJMON%=Y],.S/K=UL3[?W
M?J/3ER5U?ZJS9=4-OGU1@HR'-N)(R.*]<M6DQ42P:UJ+0EG+B3LA+5"`5CSB
M#C.V>Q,&,L>T6[-VM@L=G,]875D+>*ZM1<Z^:WENJ@`R::,7(0CBH)X`UD,4
ML:8ZXN3$DLJ,N@9>KGP]OKX5Z_I`O*ZW/=GL%U:+V]G.\VI=$D1!=4U[3=V^
M?:DJ32!S-&JCZ6R_`T+X,2,U8G4`(4'-J@]H$J0`()-$$=3YB-N[>B[>[7WD
M<%;;<WODC*+FSA7R08T7@YM^'1Q"LI91(HE"2%F`(^YF&$6D%QY2PW3Z]2CA
MP]GV#Z>/&OJ/>3[RV!@%/:CTYK)9-B5G:]\7^])43G5\OD,+E#PSPNOW?*EA
MPZ1A0F=#D"MYE;>8,G&1`&<45G(<YQC.+/Y2]N[7R>>SF>WA:6MYA<;C$)6X
MB26-6EF71^F0%0P2-P#S`+<:\[>A@>:66Y56B1/$`@:GGQ]0-<UM[M/G-@=!
M=(V]6<Q=D>VNS@Z[TUCSNQ/BELF:._E3]F#6!(DCH0:6Y-CXJ8HTX.Q"HL81
MISG),9@6,Y#S+X/LSCL7\S&1P67MT;9&'\_*.KH&B-D$\Z!"I!5D#R)&RD$,
M(W&G.O<>-2/-O%(/^5CU<\.'3S'T`D`^PU+GW=6^;3O'0-Z2W=8$LLFU*AV,
MN.J93)9S*7*92@[Y-6,TD0)5\@=E:Y<O(;R)/E,FR(T0<$$!P#P!@..0?YJ=
MM8;;O<V-]O6L%IA;[%6MS''#&L48Z@\;%44`*6,?4W`<22>-6V?@BAO@85"Q
M/&K``:#T<OHKVO?GM'9=(ZJ5U1NOLL?HALGN?>E>4%4[S$GE='Y:RI5T@:U\
ML?F-Z;#TR]K,P'*%H,4%#`(K#U@6!8_+RA\L^S<1N+>EUN/=$$4^TL!C9[RY
M25`\3D(PB1T8%6_CRA2"#Y6E?,';1S7333@&VA0LVHU'J!'V3]%>A]W]VEM>
MX=<+EURV2EDEENS&E5]3JG+*=9L\+Y!,'1E5/KPNC#F]O;L>H=78Q&[(GAG*
M/.$(64[25\;.,XY<_,[LW"8'=EANO:4$,&T=P8R&Z@6%`D2N$42*B*`JZJ8I
M2!_&D->L[;10W"7%N`+>:,,-.`Y<=/X#]->9W>;MWM1C;JSJ!J/+&J![/;TV
M\VUC%[&6G)!*:OB)3[&&=WDZ5,M0.28A6\.\H2(2U0RAC3IO:S"`^T@)&7X^
M7CM[MO<<N9WUOB![G9^W+%KB2``Z7$I21EC)#*2%6-G*@@,W0&]PL#YP]G#,
M9+NZ!:VA34CTG0\/HTY>RNO:F]7MTZY7;7EWSWLTW.V45QYGE2.>5G;DO.<J
MGG#I)8VK94SFABN'4WYN@CJ]5A:D+.,<\A,)!C`@9\1<P6]N\6W]U[>NMNXS
M:&`Q*2R1F&XMH@MS"L<@<J9.D=?6HZ&($?`G4'E5*ZR,5Q"84MXHP=-"H&HX
M@\3IQ]'#3GQUX5"WWEVZ;8IBB-0U=6W?9E#@E^U#;%9Q+ZPG#]!73$+60F1C
M=A.+@Q+48U2!J*!E;@L[U"0FD!'D.?+S8'RC[?PF?W)G4S..L\D8,*TD,5Q"
MDR^:)4Z>E7!T9C[FHT.C$:\:O=NPQ332B5%?2/4`@'CJ/37?.JF(:TI+ALJ0
M4-VW[`]A3B@KDEHD=;6E>".T8Q!T+S)6U6WS9,TI6M#[`^&*&(Q"4I\V<>@H
M.!X?&QG$9[T7^[GP5I:[EV/B]KQ-==23V]H;>28K&P,18LVJ:.'*^E5/A5MD
MY)S&J36L<''755Z2>?#V?YJ^0[`[BMN'=T/4#6$2L^?QBMK(37>*PX`P2U\:
M8;.A-3&I-;,RZ-H5I#3(<MQH<"(]J*-](6/$/AGE_P!L,#@[_P"7_?68OK.U
MFRUHUIY$SQ(TL/4X#>5(063J'/I(U\:J6,,3X>ZE95,BE=#H-1Q\#X5\!W\W
M=<U06UU/-U3VQ8U9M]A[AH8U/D,"F<@B:2;1T<HJ-.)BE:=D7HBG]H$0Y*`9
M3*L&%9">9CR^`Q>.3^67;N`SN$WM+F[*TO);7`F2$S1)(8G\NY/7&74]#:JI
MZET/`<>`JI@X(9HKHRJK%8M1J`=#HW+7E5P>Z6ICSM_7L8@;+LQL/JZHCDS3
MRXV9ZW3,N$2Y^((97AGS&'IQ-1K0JHZ<-VPJ$3Y<>*E,4+Q^+X<T3V_WO!L7
M*39*XQ&*S*2VYB\J_B,T2$NK>8B@C20=/2#_`*K,/&L39W0M9"[1QR@C31QJ
M!QYCUUFHZ@=9K[VTLG9J5V-V2[_!2Z:[M.-6QN*)[S=5T9LN*UL^DNA">QV]
M["Y^W`DQ;?[,XD)1)DYB<T80AQYO@ZW[Z;OVULC$XBRQ6T]L=>?V\MQ)(;-5
MDMY)T*DP,G3IY?5U1ENI@P!UJ196X@M8XUCMX/PT/43T\03Z/9X593[QI;UK
MTKHK7,LIVRYY54I6[<4E'%DCKN5O<.?%4?=6V=C<V10Z,"U"M.:7`:0H1R<0
M\E&Y*#Y@Y\N.:C^53!87<'<>ZLL]:6U[9KA+N01SQI*@=6AZ7"N"`RZG1M-1
MJ=#QK&8&**:\9)5#+Y9.A`/B/35N>SU],NKVM-U;%R-N4/353-5RRQ5+,F-]
M%2^'1MC4N*)E*4Y+-PF,>7`HI-@W(18*]7SYQG&/#FC]G[:N-X[NQ^U;5Q'-
MD+V.`.>(02.%+D<->E=6T\=-*QEM`US<);KP+L!]GQK,5I!I=V`]J].8WSV!
M[/\`9_7PJ]'&<N].4]KG)'".0V`QYNDSK'6-2-$FDB-M^14ZQH.`2W`2$N)Z
M4LLY4XB4&C\O7_<3?_;'LOGO_C7;&S\/E&QJ0K=75]&LDLSM&KN-3&6ZR&!,
MA8QAB52+H`J17MW8XV3X&"VC<H`&9@"2=-3S'/U\O5I6K:J82LK6KZYKMQEL
M@GSA!(+$X>X3J5JU"Z431?&V)`SK)9(UBI2M4*7R1J48EBL8SC1"/.%G(A?E
MYQ9FLA'E\Q=Y6*"*VBN;F2588P!'$)'+".,``!$!Z5``X`<*C4KB25I``H9B
M=!R&IY#U"L)._O9IN>3V"W%N;1EH6D1I'I9M92^MSY"(S8$@15A-W./ER)PF
M2)ZB#:N*89$FGJV)2$@Y6<4/R%J6P&19R,GP_2'MEVAV`W:^PV#N.SLSW#W!
MA;N_262%#<0J_0L125@70PK+`P4$:E9CIP:IK8XZS^!2TG5?C)HF<$@:C7EH
M>8TU'\-;T8;+H_/XA%9W$W`EWBTUC;'+8TZI\^)#FP2-L2O#,X$YQG.,E+6Y
M868'_L%S\UK^QNL9?38V]4I>V\SQ2*>:O&Q1U/K#`BH0Z,CE&X,"0?:*SZ=1
M=TW%8W9;W5P:P;5L2<0JK]@FEGK2(RV8/T@C=?-!D[N-(8UPME=%REOC3>-*
MV)BLDI"R@9+3EA\/``?#I_OEM_`XKM)V^R.+LK6VR%YBV>XEBB1))V$-J>J5
MU`:1M68ZL2=6/I-9[*PQ1XZS>-55VCXD``G@O/TU,'O%V$O_`%BZV[TM;6LY
MX:;)1G0U@',V%O-<':NXG))2VM4MG"(04JPAK/:68\PL+@<#TF[*C"GS!&4`
M6()\NNU]L;P[LXW"[M$;XEA*_E.W2L\L<;-%">(+!F`/0#J_3T:$$BK/#P07
M&02*XT\OB=#XD#@/]'C5:71[0&NMFRRN]QZ\[0-E]I+T9J]4K+ZHNQ+//4-#
M+,+#C)K1(2Y96TA"?+@-L>?U(_DM>8H4HU*A(4<4>/&0XQMSYB=S[JQ%E=;#
MRNSL1AMN270%G>06X#/%#(&3RYTTBZG0#S$"JRJS*5!UK(YF:>-6M9+:.*'J
M]U@/`'AH1PUT''Q&IK4WSC2HU3BE0%[3I?+(!UR[HS6"R9^ADQC&O5BO,;E<
M6=EK%(H^[HF0\U&Z,SPVG)U[:X)#<8$6<2,`P"QXXSCFS.S-C99/NMM_'Y*&
M*XL)LI`DD<BAT=2X!5U8%64^(((-7V,19,A"C@%#(-0>(/&N6]*$^G5H]6^H
M$^LN92BP9S)(-)5<AF4T?7*2RA]5$65-D)*EW?'=0K<G$\E$E*)"(TP0@E%A
M#C/@'&.9GY@\9C<-WDSN,Q%O#:XZ&YC"11(L<:`P1$A44!5!))T`'$DU4R\:
M19*6.,!4##0`:#D/`5D;2]K&U>H'<1L+8M@6_>%A:B0+<^X*>M&OG^92Z55O
M$*YEU@S!L:0,$=7.*ECC[[#6V.&NC&22`D1I+.>D*_1F&!YW"_9?9>^NP^+Q
M6,L<=:[YN=OVMU;SI%%'/+/%!$S=<@4.Z2M((YB2=#*KGB`:E1QEK=8F..-$
M6Z:%6!``)(`YGF0==#[:T<U?>T]E_O!5EUVT6W+I#0*WKDA%F1."(YD[.%6'
MNS[+X<-).F2-`7&1S+DZ-*_.0.!1/JFD'9^/D(N<HYC;>-L?EAM,K/8P1;F7
M=<MO),8E6X"I%+K"\FGF=*L.*$Z`CEJ*C\D")@UD*@3^>03IQX`\->?T5XO>
MOO7?^OS3K#J%J.ZXB.R&\ME$5U&K+P>@*5UU'B9)#(VI6LPE@S0('^0OLT1I
M2EII`RTB$"PPK(502!!J?+AVWVSN>?,;YWPGG[3VY:&>2WT.D[F.60!].:(D
M3,4!!9S&#JA8%A;*"X,EU=<;>%=2/2="?ITTY>SPKIFJG4S?=`W34MU65VG;
MG[$FPE7)W6>5;/Y4[8JBQ7-]CSJTM9>8\9+'$YI;(\Y.N5V"5!CD%2>G)\,)
M\!SC.(WIWMVUN;;]]M_$[,P&*6X6-8;B&-?B8%1U9O?\I0S.J]&JB/I#-];6
MJ=UE()XGACMH8P=-"`.H:$>.GJT\/IJ[7G/58>L/O0=TV:[;$5+9-K[U:TV6
MHL*!7DG9X-$[3_697$96Q9!"XN]$K54"/%&$\K2GOKJK+/-5`5)C@E8(R'R@
M&$7Z(_,QWZW5M;.6F$[<9>T&+N<<7FEMOAYY!(TLB$"8>88R$52`I5AKU:ZD
M$3+.9>X@E6*RD7RV3B1H3KJ1SXZ<*V86BS$)*4L2/1YI*3)4U6RYF8V-E0`*
M(3D$Q-P1-C2TMB$H("BBBP@)(()!C`<8"``?R8YP/AKAGW#:W5TY+F\B=W=M
M229%+,S$\^9+$^DDU$HB3,K,>/4-2?;7\\[430W9G6K5;7SM1J_6N53BZM?-
MDI?$KSUIL^I'5X?9Y39N8@7%9G$H%)XPI?$+FRG.JU#ER;DHU:$9Z=S39#EO
M4Y'^H^^>Y6T-V[TRG9G,9>&WV_E,3%+9W]O<JB0W0\WS(I9HY`A5PJ/Y;L%<
M!H7U\U-)W<W]M=7$F-DD"PR1@JX.FC<=03KXZ:Z'GR\16]5T%%][-,),A:"Y
M="8UL_0LMBWLLPC;I%)O"OUB1!UC+B@D<8?$B9Q:Y#%EZ\TE2087D.3DXO((
M98@C%^:D/QG;??\`#+.8+B[P^2BDUBD62&7R)5D5HY$)5DD4`J0==&X@$$"$
MJ6LKL,="T;@\.(.AU_AK*WUW=C5K],U23WK]W9T[V<D\DJ"=SYRIZ84O7V95
M$)PUR1Q)>"F=O>EIS(C6LCS(URMP;W=,8L\$C@`E002<3D&>SNZ?:G"=_,Y;
M=S^WN>P\-I?VT*W45U-Y<L+1J4+,@#D.B*J/$P7WD+*S*VM26_L(LO*M]9RQ
MA74!@QT(TX>OPX$'T58ETQZU;#V+L_M_VT[7UY)*:F^UQI40I&GI7E21)8E2
MA*IA7)5TC;5R5(XH<FML38FYM"I*3*#"D"I2).44J(QG5??W=NUL5L[!=D=E
M745_CL(#+=W4>ACENR'!$;`E3HTDSR=)9071`Q9&JPR]Q!';18NU8.D7%F'(
MMQY?9)//F/15/GO6:?(-SM;57Q/*?K">1CP_M^9):LP,%Y_@_L^"S'E^'/P^
M/Y/SW_R[G7:U\OHR'VX4_P`U1F3GKZJS),DEDT9.4*(Q)9'&5"LH!"M1&W]W
M8#U9!8\F%D*CFA8C-4DEF9R((!Y$$(L^.,>/-\3VMK=:?%112]/+K17TUYZ=
M0.FOCI5.KK:'E\P=J+KH#O,):[@6Q@(5H'63OKD!:$2];@05H%R\\*L(L!QX
MX,P+&?#EA_5N-CE\R.VMED!U!$48(/I!"Z@^L5H_<L]P,Y=1B1_+\S33J.FF
M@X::Z:5T7\^/]X/_`!8Y=BH[6W'=)I=7[K[VE9&)K<7M[>-1KB;&AF9T*IS=
MG5S75&_ID+<V-J(H]8O7K5)H2R22@#,-,%@(<9SG&.<%]OIX;;N=AKBY=([>
M/.6K,[$*JJ+E"69CH%4#B22`!Q-=1XPA;BW9CH`Z?;%4B=+/2SINW:T:J;;W
M=0<M==HCF,<O<F>Y7*7@:H-+VF4/R!M5(JD>ODQE;%*=*WI59('%"I$4>$M0
M7Y18`+'0_?\`^8'?LN[<ULC;V3@39PD$2M:K%U31-&C,#<KU.P)9E)1UU&JG
M4:BLWE<Q>--);1.!;G3ZNG$$#QY_8T]=6Q=PL:D<PZQ-V(Q$8^^2J3/=&25`
MRQV--*]]?G=<:<A])&UL[6G5.#@J,QC/E+*+&//AGX.:3[$W=I8=W]O7E]+'
M#9QY&-G>1E1%`!XLS$*H]9(K&XIU3(PNY`4.-358W7]U7:=2?JHIJ;W1I#6J
M_8I=KU+'24N,\JPQ-9Y\U3XE?R<>\(W1&G?@/_B0G]((R@G9\`>7']GFX.YW
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M*;J[.=N.TN![5;TM[G,M<6ZY"ZCL+E`([F1F;2>2.:,EE+%%34Z"%68?4-9&
M2XQMGCHK"X!DU'6P4\FU/,ZCQY>H`^BI&]&%7;1:!;N;IZ$["QAS>8O.4C!L
M)"K@A$(EZ*AGJ?'HFTZ8(H8_*H^VQYJ,?H]*$A8D&?0$F/C9I``8P$.,Q3YC
M<SLWN;V\V_W*VO,D=[;,]E+:S2Q&\2$%A$94#L[=#QL>OCU"=6)XFJ&:EMKZ
MSAO8#HZ^Z5)'5IX:\3R(_AUKZ?N@TBSO5V8==-,2Z)6(?3<PIK:"-3:RH?&W
MA>T5N_#BRM]@3V\/Q*$Z/MRA%,&="H*2+SBBW#!>4_Y#/'EIV`[A_P#QQVCW
M5G[&>U&>@O\`'R102R*K3IY@29%0D.P,3NI9`2FO5X5YQ%[\%CYY4(\X.A`/
MB-0"/L'[OA70>C6P-@]9I%:/5CM;0Z^$RBB'!P5TO?,+J-UC]47?"4I1!IN7
M.>-3"FC+[,,M1I#FA<%9^'!Q0'&IE?@O0&^MB_F,Q>U]W6MGWFV5DEN+/)(H
MNK.6Y5[FTE.H'3"SF1(NH-&Z*.A'`>/\%*.GQFD@N0N2M7ZE<>\I;4J?9KJ!
MX:<O$<#PZ%O)")M<W>+U31(N'RQQJREJVV!N.62HF./2F#MSS(HY(F5J:7>2
M%(AL2-T6*(2F`%,8>$X85`,>7P,#G.*[=9''8#Y=MZ7IG@7,Y"[LK6.,N@F*
MQR1NS+&3UE0)F/4!I[IX\#5&SD2'$7))'FNR@>G@1_XOX#Z#5,NC_79L)6?<
M9%-1)7!YY_\`C+3?9*[=RJPF3C$Y$"$O!TEAD+(JH269J2<Q9S=TIB2,E#2)
MS<J"%C>XB%C.?/@._>XG=3:^7[#S;YLKFV_]_9[$VF+N(EE3S5$<LIN=8@?,
M53K<$,PZ2KQ`>&N8O;^WEQ)NU8?&2QJA&HUX$]7#GXM]D5;UT>U1.];]D^W?
M7V0P>:QB!->WOZS*C?'R+/K/%I5%9X?,P84Q-[7H4[0^%HFAG:@G>QFG8+\X
M<"\/@\=&_,3F\;NS:6QMT6MS;S9-\%\/<HDB-)')"(N$B`EDU9Y-.H#70Z5B
MLS*ES;VLZD%_*Z6X\01IS^R:AKOA4>\G8?W0LS/JFL;*::NNFL6>0UW<UWU[
M*G"H5ELO;HTNLH71HE?$GM@ELF"I?T"1/Y"3R"<QLT_S8$67G,][;9SMSVM[
M`23[T5[^?=5XR3VMI/&MR+9%98Q(1*CQQZ([-Q#'SPNFA-7=E-96&(/Q.K-.
MVA53QZ?#Q'#@=>/CI7C:9TGOQUZ]T[>];3'MUY,O8=6[ZFMFYZ"K&5(ZG:+$
M:%0E$-7S).VP]A8(C)"G>-!3GGC)(3G%242C(\CR?G'O?VX>V?='Y?VM]FA\
M=<[6NT-M:WMQ&;EH&&DJQ%I7>2/IDZE`)8&`+IITU]NY[&^Q'3;ZHT#>ZK'C
MIXZ<3PT/#CX:5)CW@+5+8!QG&F78UK)6JBWIQI'.DS].Z[:4;B[2)\A3=,8M
M.6%Q0,+66I='MK97UD5$.1:$HQ<G2.6502S"TYGIQ#Y8]Z[8BQV?[4[ONQ8X
M[<5L4AG8JJ)*T4D+JSMHJ,Z.IC+D(S1]!(+#6WP=U"$EQ]PW1',-`?0="#]/
M+37APJ5.G'=S!MR+NK:AXYIGNC7,DEB.2_/J66#50$%;5.[QYC='DIMD\J3.
M!QV4[R8U^R)U)J1'CVM026,`<BS@,,W[\O.1V%MZ[W)=Y_;]W:0-'Y,<%QK/
M<J[JO5'&5`U7JZF4,WNJQ!.G&UN\.]I$TS30LHTT`/%M?0/X?&HF>\ZUW-;!
MH;3@$2JNP+;01O;-JD,UC=>P>0SQR^9R.%2/Y:PM:H\@7&@1N"3(TN,G>D48
M8:$O(\9%R;_)_E<?B]RYXWU[:V,LV$9(I)YDA7S3*G1HSD#53HW#4@#73A5W
MMR1(YY>IE4F+0$D#CJ/34J>K>V-!Y3;EC1?4/KMO?3:4J:[)?9=-+*U=S1<;
MEK`RR1M0HHP1(?EMRP[/)#C(/:B4>2P_H`'&8%\3..0OO)A.Y=G@[2]WSNK&
MY^S%UT116^0^,DC=XV)D*="]*%4Z2VO,J-.-6F2BO5C5[J=)AKH`&ZB.?JY?
MY>-1P[LHI=E-[E]:78S`J=G5Y59JU+)PP7-%:OC#G+9LPQZ:!;BC9"4SMOQQ
M(SF,UP+3J#,EI2'(E.!0,`#PYY+/E[OMO9[8.[NU.3O[;'9G,P0O:R7$BQPN
M\740A9O$.$+*-6,98H"5-7.'>&6TN,?(P224`J2=!J/].GKTY5#O8^_E7>EN
M-UTPK577S96(U=J]>GZ[[PNJY*X)@,8CC"V/,#=E+0VY.=W-"Y/6017T"B/:
M@JCU*PK!1`R@''%SO:6V4^7'8>Z\AO/*8B?,YC&_"6EI:SF:21V290S:*K*G
MX34GIZ0JG5@Q53=VT(PUI</<R1F21.E54DDGCZAPX_Z:V,\X.J)UG?Z!Z\L"
M`NW:*.>02:0@$H["+3D,8%,(L^QD,CCZH]7E*^L&7M`AP\,RG&<>FJ3^H0/Q
M^`6>=2_,SE,7DX-G#&W-O<&':]NDGE2))Y;@#5'Z">EAXJVA'HK/9R2.06WE
ML#I``=/`U[;WDVOY]9&A5;,-=0:96`^IMP*.>%+)!XN^2UW3M"!LGV%SJ>V,
M"%P6E-J,1Y>#3Q`P47DP.!"QD6/&A\IF4QF)[EW=SE;FWM;8X*[4/-(D:EF:
M'10SE1U'0Z#74Z'T5XP$B17K-(0J^61Q.GB*M7W@H)[VDTRV/UWC;HD9)-;U
M+S.$1QR<?,%N2R)T8SP,>',82CC"&TYV`26I,"`8RB1B$$(A!P'.E^W>YK?9
MN_L3NF[1I+.QR$4TBK]8HKCKZ>6K!=2H)`)T!(%8ZRG6VNX[AAJJ."?9XUE[
MZWNV*R>LBA6?0'=C1K<(=D4>\S9F@+A5-4ERM'(XX\2!QD;(R`$>YLR9[S\O
MNRTA&\-9S@@6H,IS`BR+`_'L3NQV4Q/=[<LG<[M]N/!?U3D8X7F6YN3&4D5%
MC=^"N4]Q4+Q2!'1^L$::5),CC(\C.;^SFB\MP-=3R/+7D=.'@=..M:.]K-KY
M+6_758NUT%K>R"K!<J!02VNJL.A[TKLUHL:R&%N1PJ,OT/;4*YV3O46E,D38
M=R0E"]E"D/$+.`@R+'*6R]E6F6[J6NRLE=VAQ:9-HI[@2H+=H('8RR)*Q"E)
M(XV\HZ^]U+IQ.E1^VMEDOUMG9?+#Z%M>!`YD'U@<*R9ZZ=-_;E/.LYZK=LMR
MA8'2>R"<[867:[V=6[@*]GJ8>=HD$<4OLO4U\K?8W-7T,.:STQ&',K"#"C!)
MV"Q"4@YVUNOOUV/QO=Z/+36.2N=PXDBQBOK>=?@TB]Y'"1"<))$GFR!CY9Z^
MGJ74!#4GN,MBTR0D*NTL?N!@?=TX@Z#JT(&I\./V*O\`O=Z[5MB9]=4%JV\*
M^LBN[%UN?WBG<(+,ALJA[L\P-#Z+]73JB*E#:W#<$3;''D++YR/.``VG.,YQ
MXX\>8_FBPN$L.ZESF=NW5I=8K+1)=:V\L<JI,VJ3J3&S:%I%\W0Z$B6L)GHX
MER#20,K1R#JX$'CX\O7Q^FJG=4-JG#KO[+>WV:6_JANM/HQ?FQZ]37;Y2.N,
MKGC4XH8I.;.6+'(;FK.C[:<VN*>4)A(STIRDL\.!Y\<8P'(MV;VV9%W3[1[%
MQ^"S>WK:\QF)`G2[OHX64R0VX"](#MU*8V#!@I'#GX9.[MA?XZT2*6)6CCX]
M3:<POHU/A6ER^MM(+6>DSKMK+::MF=5POKF$2V04PD@*5SMD^)6<ICC4N8'V
MN'9:!&)U8FV5Y&]-J@_)91*92`8LX#GQY'VULC)9?N$FR+*_LK;++=31I=&8
MK;"2W$C!TG4:]+M'I$ZKJ2R$#C4=AM7>\^&5U60,1U:\-5UX@CCQTX:>JLIF
MM=;USMKW):Q;)=8.I%\:C4;5WM\LVSELX@SA3U</8QB<BSXG&8DW.3M'$"J8
M-!A:$UJ0'%IEHSL*A(B`HSE)O:6[<ME=D=A<QM+O#G,;G-QWG3'C8H9A=3I]
M72221E61A$VKB1P60#H$C%U19-<2R6V)DM\C*DLS<$`.I'K).A.G/4\O3X5I
M*[1>R^-=8=657:LLIZ96XRV1;C56"PN*NS>Q%11.K9W9^6OJYP<D2Y,J6A;F
M8["%OSZ&5YP<A]<G`<BYR;V<[1W?>#,WN%L;^"QN+2Q:X'F*S^80RH$"J00.
MIAUO[W0./2VNE1_&XYLC*T2,%95UX\=?\O$\=/15EZ%84X(D:]/@>"%R5.L)
MP:#)9F"E)0#B\&`SXY`/R#QXX_-GFHY$:*1HF^LI(/M!TK'D:'2H"=KL??Y5
MUL[M1N+,;S)I&]ZZ60W,L?CS6N>WQX<%+&>6F0-30V$*G!Q6J!Y\H"B2QF#S
M\&,9YLSLK=6UEW:V]=WDD<-I'E8&=W8(BJ'&K,S$*H'B20!5]BV5,C"S$!1(
M.)KE/1[%)3".JC3B*S6,R&'2EF@<G3O$:E;*Y1V0M)YEFSE262YLKPF1N2`T
MQ,>`P(32@9$6,(L?%%C.<U\Q-[9Y'O1GKW'S13V<ES&5DC=71A\/"-5=25/$
M$<#S!%5,PZR9*5T(*EAH1[!5)^D>A:K:78SWA*A[\KB=PVN=@[ER97\XDT(?
MF5O&_MEPW\_0NQJ_=7MN0M\A41)X/0.)9B(XPLT@S!8Q>BHSYNA.X7<I-F;4
M[7;DVS=VUQE<78?AX8YD=NAK6R26"948L@E4.A#@$$:@=2\,S>WPMH+">!E,
MD:<0"#PZ5!!]O*N'^[^Z_P"WU(]HMI0S9R`VD@Q2&J\]U]89O)8I*`0,]FA=
MN08Z-L<*G;BVE,C_`!LU*H4JF;!*HW/R8,(2\8+*P$$C^9S<VQ=P]F[/(;/N
M;)CD<U#>O#')'YP:6VF\QY85;K20$*LNJC\)J3Q;4ULY/:38Q7MF7WY0Q`(U
MXJ==1X'T^NK#/>%]0MDIC(M-]]]3J_=[5LS3.=B>I%!&)N4R1[41])*8G/HQ
M(F^'HRCG"2-['*(F,AU(1`-681N&#@E"+(,$7JWY7-\[3L+3/=L][7266(S]
MMT),["-`YCEAD1I3HL;/'(#&7(3J3I)!8`X_`W5NBRV5TP6.9=`3P\""-?#4
M'AKZ*DYIQWKU;N+=-2:_Q[4G<&!3^>%2(,Y=IE61)%=U.J88\YO1)DAE25S-
M6'-#TK;,HDZHQ`CP!2>2$T(,CSC$/W[\N&9V'M^^W/=9S!7.,MBGDK%<$SW(
M=U0]$94`,@;K90[:J&()TJWN\+):1/.TL3(NFFAXMJ?#PU]6IJ4G9!V,&=>S
M=0:\O6ZV-A?UXV=FNQ!K(`PE0O!93<;EP=CBV5\$K='+#CGY-;\`(RNRF4?I
MR_2^-#>U':H=T)<G$<M98O\`JZS\_P#YC_B_6X*.M-%7I_"/J>CJ7W3KPM;"
MQ^.+CK5.E=>/CS]8X>D^&HJR_FHZQ].*4XI3BE.*4XI5,/;WU#PGLKA#/*X[
M(,5]LU6#`XM-93-><M41!_95*HQV-@$]:B?7R6R+G00C$[DC*]N;CS1#\J@G
M(TX]I=M.Y5WL2[:VG3SL#<.#*@TZU8#3S(S_`*P'`J3TL!I[IT8>&7J]M?SK
M;SHFW-:;2E-+7G!7FN[*AROV9YCKR5C](G-R+*!Z97`G(T$@C3P0'UD+BD,-
M2JBL^(!^.!8#VSB,OC<]CX\KB)EGL91JK+_"K#FK+R93H0>8JB00=#5I>O&<
M!HRLA"S@(0Q@.1"SG&,8QA>OSG.<Y^#&,8Y<OQ<@>FM$[F_;]W^5^X*O^Z_N
MK&1WH-EM_8!$ZQ"F\Y3N4>B`\'MDKLXK`@')U"CQ])7&X2I#X9]?XJUP+S^@
M](H6%&=%]R.[UKMX283;;)/G>*O)P:.#P('@\H]'U4/UM2.FL[MK9\N1*WV2
M!2PYJO)I/_"GKYMX:#C6J(@@I*02F3@"40G*+()*#X^4LHH&"RP!\<YSY0`#
MC&.<@LS.Q=N+$ZGVFMP@`#0<A7_7GFOM.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI4/]G=+*OVVF
M^MDHMUXE[C&=:K5%<K+4Z5<U8K*P9T@95;;$76R6)8T+%CZ*"KU65K8`M2G)
M":,T!P#BC1`Y.MG]P,QLC'9:SP<<"7F7LOA7N2&^(@A+AI5@<,`GG`=$A*L=
M`I4JR@U=6]W):I(L0'5(O3U<=0/'3V^/T>(J8'(+5K3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*571V+]9NOG8_5V(E:+=\V;)C:1;FJ[KCZ),.:0!Q4
M8R;[,+)F20R2'+U.`Y7LRHS"=1CQ&4).I"6H+F^R-^9K8V0^)Q[>982$>=`Q
M/1(!X_[+@?5<<1R.JZJ?+*&%0'ZU>E,G71EB[OM>XQ"S997BE8VPZ'QOVMPK
MTT+2]+A-,W?@NZ-&I>5CFGP6J2M9Y/LR'`\8/]H.QC!6S=_=[ILS:?U9M-9;
M6WEC'G2MH)?>'O11])/2!J5:0'J;^+TCZT0AVG;R9J?+Y#20-+U1I_%&@&C-
MZ3PX+R'CJ>6@[&,!Q@(<8"$.,8"'&,8QC&,>&,8QCX,8QCG/?/B:F-?O%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OS`L"^$.<9QC.0YSC.,_"
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M<`HPA.\D9'@6`8Y.\IMNTV(^XKZQQ]AD(#)C)[`S1K>1"SOQ<RCRB&*/T]*P
MF4$@M$VG.KR2!;3SG1$<:QE-1U#I?J/#T^C7U5ZZ([7V]2D9I_:RXK5D<YU>
MC,WW%U6ELC4K&=P26G$(/-90HU)V3,3,#:@9U5A3U?5)T*&M0@3HI"OE:$X@
MD(3R>5K[96"W#=W^R\#916V\9K;%Y&*,!E-O+-%&,G8:NS,((5N1=A'+/`EM
M(K-JK5]>UAF9[6%0MR1&X'^J2!UIQ\!U=7'D%->JV*V*VPJ^(ZT5`QOUURC:
MMNA<CWIOV*5)6#]:ZYP3E2\;A#M3)"DC+2YAAE23J1R-VBJ5U'@@9*&'!$$S
M)@S!9K;5VKLG,7V7SMS'CX=EO<1X>RDN;A+8*3%TRY)#(R^;<PQQQW+1C4%[
MK0C0"OMO;VLC22L$%MU"-2S!?#BXUYL``VGI:O6;+;NW/7TWVGV%@=AO;]IL
M/4.G!#3M3=E0\4/)[LJ^W914&SL9&F3J5V(Z;+D;<R2M+D)GL12U$Z?^2W+`
MYJ[2[>;?R>/PVV,G:QQ;\&<NN+-HEY':7%M'=8^34@>9Y1>6V;4=922'ZTJ&
MO,%G"42*4`7(D;GH`0A'4I]>AU''3AIS-=?52>175-+88[JW&M'5^-T#JMKE
M9L-5U_-V>LSU^9[7DHDEB;$6"XO#0J+L]B:)5'A-1;<:8./I!LZL*M,8<LP(
M.#2SM=OX^RN-OX&SS%WD\U?6\HFA:X"^3/''!8P*K#X=VC?S#(`)F$J%'"Q\
M?/2L**885D9Y7!U!/(@!!Z-0==>9U&AX5Z.[+FON6P[:AIJ78][C4@7+^K%E
MIZUTT7PVML57[`SZ$,TEFJ6NGDD2IM9YP!YP>Z,BL63O9#1I<B`/X<7&WL!M
MJQO\-/F\3'-:JNXGNK8R=32"RAE>.(SH=&:'HTCE7AU`/Q%?888%>(RQ@KI-
MU+KSZ0=!KZO`_37PAV\5VS@K9YKD<R>-=IC7TOZ^=<K[1!2$N"#6B96G;]@P
M.^Y[6KD_-ZYFRQ2Z&.#0]QJ4.!:EN+:%K>O/+P,DTH.27MUM['-AYK2"/*V%
MU!FKZS.I4W\5O:P36<,ZHP?KBE66*>W0JYE26)3HRFO8LH4,94"1&$KK_MA5
M!4'3T'4$#CKJ*G!J7+%<6V?V$UR43_8>9H(S`:]LF.)[RL&J+=0@9GF4SZ)?
M/&$3J'R9VLAI:IR*/`SE@EB5,<DRW>TI/)A2H*#KO>]DE[L[%[K6UQ=O+-<S
MP2&S@N;8]:1PR^5+#+&L#-#UG\-;,P;KZ'UZ%)L[I0UM'/TQJ2Q!Z0R^`.A!
M&G#7FOIT-1?MF>S2(N^X5_I=G+589]3.X]>UC4%,J)VF<*GF#.Z0;7'TJF-I
MXY":-_.L%98CN6$Y&(#L0K4`5ICBQ)L<F.$QF/OH,#MA\/92XS(8&>XNKH0E
M;F)EFO\`_F?B@?<$`@B.C:QE5*.I#U<PQHXB@,:F-XB6;3WAQ?WNKPTT'/AX
M5Q^SK8V%8[QL6:(I;LQ$HJV]@T4IA)=SU=,,+T]K*$J'.M$AD5F]-%%R27C;
MI,!S4QPM4L:6]NP_O:0[+ND\2S@YW#X3:USMVUQ\D&(GO7VO)=&T2TE_K2XE
M"SGS(;K\'%U1]*SE5D=_)B=1`_%35CB@:!4(C+^06Z>D^83QXAN`X<^!)T!X
M&I3+MC9@CJ2V$2NW%K=9$9[4HA292)<[(D,H;:_EFXE7$L-?I&]662I4,D@H
M^8$Y2EE%F"/95N#`#SCQ$&&1[4L),Y92)8JV)FV9+=ZA28VFCQ=P7G+#4!TN
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M:Q=*VL\4,1:%XI'+3`UX2&-K41A%$IC9O>4ZMIJ>I9`2!II]4@#@03QJ17;D
M&:Q;4Y^N*NKDN.H9I7<JJ9H:E573I1$V]V169>M3P&0AD[:%(L2/AA$<>E9:
M$1H?%&:H$8#XWAR*]CCC[S>T6!RMA87V/NH;EF%Q")&4V]G<S)Y;:@IK(BE]
M/K!0#PJWQ?0UR(I$1T8-]8:\E8C3T<>=>!()OL;26T:FDZ;CDQV5B,<T[@LF
M6H[/OQHBSXT2)QN"X6X<U<I')8N^*I6_OC<VDHAF^!04R=M)P+&?-CPJVN.V
MIN'9R[ASTMOB+Z7/31@V]DTB,BVMJWE+''(@C1&8N!QZFD;3E7T);S6WG3$1
MN92/=74:=*\-`1H/\]5T2*[]DY#7<4L$(MT;:-AG63IQ=S^'7F^(96*)FG,^
M,O(Z?3^PVAS]HDL]<'=-$4JL6&5C?C?9F<\&$(Q'%EF;5M=N[2M<K/C#_P"W
M[%;C=^4M$^.LY;@M##\((88&72.%5,K+^%FA'5*I\P!21D%AMUD,?X%>JYD4
M=:DZ@=.@'@.?B1SYU,V,O4IV!G\8K>XMYY9!F^#Z5Z[6Q')GKC-8O3;!L7)K
M*;IT1:NP;:]/#$Z+I)"HVMB#:)N;DPBV9K"Y^JX)C<JDP"H!=V]GMC&39;`[
M<@N9;C<%];217T,ET]C'`T)MK)D5U$<L@EDZW;663R](G7H<FT8)`ADAA#%I
MG4AP6*`:=*^HG4ZGF=.!X5[72_:J?S2Q*T*O6U$!:25Z+%6"QJW52W1B*VB*
M!;#63"%FP3,0<D:&HD^>UEF*/[@!-@E*B2OJ7("2B!E\H[_V7C,?B[QMMV3%
MX-Q^0X4-));^=8P3"R<@LQ$-Q\3"A;5G:%]69@:\WEJB1MY"\1-IZ2NJ`])]
MAZ@/8:X;7ML6M?4:UHB4MOF\4HQ==]<[*M$6IRP854MD;1V;*I2[Q:6J3;=F
M/R.TB0UPRHFA48@(=6I.:HE!"E6,PH!`<2+*83"[:N\O?6.-QQ__`&J>P:2Z
M@EN8,=;QQK)$/AHNMNJ=S*H<QR,%MV1`&+&JTD44#2.B)^/*$L"P0``CW1Z3
MKQT/+A7T&MFY]_6E)=>'*E6.<;(,3IKOLBT2MCM:QJHJE[6R>DMIF&GB[%?7
M.")9Y7DN>P%MBEO+7LIX$;FG.$N"`KVC!(+;=NP-LX:TRD6X)+;$W*96P:-[
M:"YN4$=WCGNO(19C#/$GO*Y24%HV`C)/3U'Y<6<$2R"8B,B1-.D,W!D+:#70
MCV'ERJ7$)O.X&OJ^DNP1QA[M=L;U_N>?)OE;/SQ$FFT5*G"UL1K,M2,CYU)(
M\M;"B<X3D`]N(3>``X\^,<@^0VY@IN\4.UU`3;TN3M(3T_@M8I#"&(ZB?++A
MB?>)Z"W$\*M&AA.2$'*$NH]'`Z?8UJ*B*S7:E;,88?'MGMF+I(NO5>\+`BME
MS"Q:#LFIK.D,+K!)8)D]@S!&W1JLJFE,64.I7LOL#(5&%I*XM/DL0RTQX9I)
MAX-P8B6^NL/B,>^/S5I!);Q07L%S;I+<&#R9GD5H+H2!3U=<IN$*%]0"ZFZ,
M8FB+M'&G1(H(`8,`6TT)^JVOK.HJ9\I?[5F^AT'L>I[6"W7?!Z<JR[D[PI<$
MJ]FG$@BD-:I?(H/9B=+@>5$3M-"0N;'`P&"ST8UF%J?.#TI?(!96V%QW<JXQ
M.;LNO;MS?W%H5"E7A225HDFMR>4EN2DB`ZA@OEM[KFK15B2]:.5=86=E]@)T
M!'K7@1Z>7C48G&Q[LF52:KSRP;]D%&,W8'?$7=7YPBCJT)\T/2TGHV>6)3M!
M5U,G-H4,[#/)RKC+*W/LH&1[4X/CFO+;!$>=L"GF$6)V]89S-8W%XR+)7&V,
M;(J+(K'XR[CO(8+J]GB5@SPPB25X;<'I2&.,S!M)NJX$<*2RQQQAS`ATU_C,
M&`9B/$#4D+X`#7QKRY=)S6Q-5VN,3W7MM_K.1;C2^J+8V&!)(V3957A;*2<;
M<C&M"BZW!@/0JGB638:!*6_@#EW*2*/D'"@+@,H>*=C9K,]YNN]V]8Q9>+`Q
M7-M8^7(;>XZKM;:2_%HK@A8XNMC"?P19?B>DQ`BB+KU7#0H)!$&5=#HWO=)?
MIU\!KPY?QN5<=G,YN]F07SKY`MOGI_B<'VOU]@]9V!/K$00VS;&%.ZN>+!L;
M35JV=;H*^MK+/4#TTHU[>_J&U4Y$H'$+$K5!/-`I*SV.QVW;B7&;HR6"CBO;
MC"7LUQ##`TMO!Y-PL$&4;'M,C/"49D>%9%C+I\2B%04-5$A8I.\0#F)B0!J!
MHV@DZ->7@1KIJ.H#3A7LH9=TYF$=H+7IYO\`NJK6-]VRO*D;UG\OE\"<[DB$
M@@M2G7%!M<6'8R-%/<*DOSL^6DZE%*2`IY`M9&\;4+*1W`JP72R&W<;8763W
M1!C,?>7$>$L[NSABBF6UE2:Y%K-?/8R%)8_*Z&5[<]4*2N)AUP%-?CPHC27`
MC1F$2LH`/206Z2Y0\1IZ.6IUXC2I#0"PE\<MW6*J8'M-,M@(8COW;2NYF_R,
MU,N>S#(73;C,FZKYG+$Z),FLI=5;\O`46\$X";YB0)E0S5B52,<6R>+CN\'F
M,UDL-;XR_;&8V>)(P0GX6Z6)KB*(DF`7**28CPXET`C=`*#QAHI)7B"/T(0!
MRXMIJ!X=0\/I'#2HGZL2'8D[5"<;"3F87I\M&Z1V38S%-Y'N,TVBQO<U45\8
M^(9`W4HAB35F!.!!I8EZ+U%"C#-D'LHL#'G(N3;>=KM5=ZVVU\=!C?AQN&W@
M>%,6UNZ1"?H*-=M*WG*1[CZ*OFZ]8T'"KJY6W^*6!`G3YP&@CTX:Z:=6O'[M
M?.PW>';2"Q9IK2=J7&?[,4/UX;);`IA@0!:XCMG'2(C0KYK_`'F%((DE%B0-
MJY8^LDF:R3P#32!(N]$.$K@@%FZO^W6R,E>OE\<$MMHY+=-A9'CU2XV0RWB7
MMGKJ3T,!#+;R$$-`T?4>N*05]:RM7/F)PMWG1?6AU8.OLY$'T$>(-=-MB5%4
M?K)>-B55V*V];-G3/KBON](Q&Y7-HM8F5BZ(PUGD3-L?6RZ.L3<@JQ(Q/,L*
M3@2$`PRNA:Y,6F("-`(6</A+)MQ;OQV*S6U;&QP]ONNRLY)(XI(-!+*R/8SA
MW8W!=(RQ8GS8RCEV(E`JG$OG7*1RVZ)&+A5)`(YG3H.I][73VCZ:],7&]E"M
M6K/D+NNV52!?(U16)BH3[B&;(3-=3CO8<75W^\5M'X?%HX]068(ZO]O%A8@$
M:X#1GG`08"K+)SFX-WM([RL[6!<0QCFO/*!Q?P$0NE@D%DD[RR.DT1N.CW7T
M0.%,FJ%J]=5O\2JCR^!;3\'T#JT/3J22".K3U>FO.ZEZ_?:Z?T#2@"P@<5\#
M;GBW\5@_L$AJA0VN]7TLY0Q7(UD*2M\.#=Z>V%$W2BP%.%W^1RE!:H]<A(9U
M9E/O=E+;*VS3R>:8EN66U^(1TN0RW%VLHC$I:7X0VPM&^MY7FE2BQR-.@^91
MUD7J.NG5[NH(;FVNFO'IZ>GU:\M#J*OOYS16#IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4J'-N?C+TW^A>T__`$.J.3S!_N%GOTC'??W-7D7]#F]J
M?;:LH?;_`/WRX/\`4;O_`/A,U5YVMV*_%V/_`&I9?^I9&I-BN2_HZ_?O5^]E
M?RA==?HEUY_?'KSSF7$_WYY7\OF_U6^K!Q_M63VR_>M4CJL_F1;@_NUZ>_6C
M9?D4S/\`=/@O[7RGYNPJWE_9\7Y23[257Y5WX/=^?]/^,?=YLWS9^8_?O;/_
M`'/)^?Q]7\O]+@_2#]M*@WW,_M2ZK/L_:?K13?-B]@_V-O3]*;\W=5>8C\5=
M>W[C5;E>'[5-K_MTZL?OPA?-';=_8N%_LW<7ZI+6+@_%Q?R)OO37^[._^_\`
M;O\`NP4?]TMW\8?]F;&_MB[_`%FTI%]2T_*M]\M5]>[3_LZVN^T*N?J0;S9_
MS;_M;"_HL_YX5?;A_&1?R3]NH^'?U)!GVJH_X6V_DH7_``FC]"/_`*@U7'_\
M]_N_SZM2V:_`3VC_`&O7#_AJVYIC:']YFS?T&U_\^L7;?TVV_DK]VH"W'_4)
MTY]'ZS^H+AS9N!_PO7_Y6X_/BK^']@O_`+WVZC;VF?SI:=^E>J?UA0<E?9K_
M``_W_P"0R7WAJXQO[(;V/]JNJ;%?U'%+_2.EONLF/,+M7_"GD/R-W^LQ52@_
M8#^QOMBKV>T?\$MF?337S^(VIN<X=F_[PK/]'O?U&YK"XW^F+_);[QJ^Z%^.
M"ROW-:W^]VY^8X?W=V?]OS_JUI7C_P##7\L?O5J.F@/]X9/].?0C_F[)<E/<
MWZDG_=>9_P"@JO?_`/GR?S*H!["?Y5G59_EDC^JRWG3G:_\`OGWG_+C_`#@K
M.6'[2NO:/MU++OH_"!H3_P"N5]UD>Y"?EJ_?K<OL/ZP]6V%_I4_^7\8U[WO^
M_!_IG_GX_NS1\M_ED_?K/_DO^H-?,'_2YO9]VIR];W]UT;_TUEWWHU7S7/=C
MZVX_^[5_5KBK+(?\;](^XU3VT[_"[7?_`,"7_7*3\UGOS]\;K^5%^:CJPN_Z
M0WT?:%91>H_\;F\7V!;'_7,KG:O?#^[S;G]IV'YJI/E/Z)!^43[5=V]WV_8G
MV!?9=77U,MSD<^9[]X=L?IL_YVVJCG?Q]O\`RC]M:G[V%_R(V#[`=3__`!K#
MFL>UO^)&3^T\E_U%6-A^VS^4?[M1G8_Z;>3_`$'<OON1\EUQ_BRA_25_5#5R
M?WA'M_FUSQ!_3;/WTA-_B90<RLG^+*+\D/U`U[/[PCV?S*YS+/Z;>*?;#G^(
MJ1<RUE_BRF_0/^A2O:_O"?Y/\T59OH#^P'I__P`DV&^[VP.:@[G?O/OK\I8_
MGX*Q^0_'W?M3[8K/5U?_`(@]E?W.=R?J_P`ZA[P_NQB/[>Q7W]9W(?B(_P`M
M'6K.*_MVT;_T^;M_Y^J'.+;S]W-Q_P#=%I]K)5&&_$S?EU_GUG4ZY?V-=U?[
ML\U_PES\ZJ[K?M_M]_:\7V[2L_D/QMG^4'\VNK>[<?B/V`^P2._7IOY@_FQ_
M=/%_VF_YDU2W#_1X_P"6?M5KFB/]U>/I/(/^H&<X?O\`Z\?Y%/O:BS\_H%?_
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
